Table 1.
The demographic and clinical characteristics of the study population
| Parameter* | ALL patients (n = 19) | IBD patients (n = 35) |
|---|---|---|
| Gender (F : M) | 6 : 13 (32% : 68%) | 19 : 16 (54% : 46%) |
| Age, median (range), years | 10 (3–17) | 39 (15–73) |
| Weight, median (range), kg | 33.4 (13.2–77.5) | 66.7 (33.6–104.3) |
| Surface area, median (range), m2 | 1.14 (0.59–2) | – |
| 6-MP daily dose, median (range), mg m−2 | 40 (5.88–76.47) | – |
| 6-MP daily dose, median (range), mg kg−1 | 1.42 (0.16–3.46) | – |
| AZA daily dose, median (range), mg kg–1† | – | 1.49 (0.47–3.17) |
| Haematological parameters | ||
| WBC, median (range), ×109 l−1 | 3.3 (1.2–9.1) | 6 (3.4–13.5) |
| PLT, median (range), ×109 l−1 | 282 (66–648) | 302 (148–601) |
| ANC, median (range), ×109 l−1 | 1.68 (0.3–8.3) | 4.24 (0.36–9.7) |
| Metabolite concentrations | ||
| 6-TGNs, median (range), pmol per 8 × 108 RBCs | 242.3 (56.1–1 114.15) | 241.7 (79.2–856.1) |
| 6-TU, median (range), pmol per 8 × 108 RBCs | 57.5 (14.3–251.7) | 33.2 (16.7–126.7) |
| 6-MP, median (range), pmol per 8 × 108 RBCs | 6.6 (2.6–43.8) | 5.2 (2.8–28.7) |
| 6-mMPNs, median (range) pmol per 8 × 108 RBCs | 5 466.1 (180.1–28 733.8) | 792.4 (100.8–13 837.8) |
*
F, female; M, male; WBC, white blood cell count; ANC, absolute neutrophil count; PLT, platelet count; RBCs, red blood cells; 6-MP, 6-mercaptopurine; AZA, azathioprine; 6-TGN, 6-thioguanine nucleotide; 6-TU, 6-thiouric acid; 6-mMPN, 6-methylmercaptopurine nucleotide.
†
AZA or AZA equivalent dose if 6-MP was administered [6-MP dose was converted to AZA dose using a conversion factor of 2.07 (Sandborn, 1996)].